Daily Cosmetic Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
Across three studies, adjunctive cetylpyridinium chloride with triamcinolone improved clinical and immunologic outcomes in oral lichen planus, a real-world analysis confirmed high agreement of an anti-nucleocapsid SARS-CoV-2 assay, and spectrophotometric data identified Artemisia maritima as a promising natural photoprotective agent. Collectively, these works span treatment optimization, diagnostic validation using real-world data, and cosmetic/pharmaco-botanical discovery.
Research Themes
- Adjunctive immunomodulatory therapy in oral lichen planus
- Real-world diagnostic performance for regulatory decisions
- Natural photoprotective and antioxidant agents
Selected Articles
1. The effects of cetylpyridinium chloride mouthwash combined with triamcinolone acetonide on oral microbiota and the Th17/Treg balance in patients with oral lichen planus.
In 80 erosive OLP patients, adding cetylpyridinium chloride mouthwash to triamcinolone improved total efficacy (95% vs 80%), pain, mucosal repair, and reduced erosive area over 4 weeks. The combination shifted the immune profile toward reduced Th17/Treg ratio, lower IL-17 and TNF-α, higher IL-10, and decreased detection of Staphylococcus and Candida, with similar mild adverse events and improved OHIP-14.
Impact: Demonstrates clinically meaningful symptom and biomarker improvements with a low-cost, accessible adjunct to standard topical steroid therapy, linking microbiome changes with immune rebalancing.
Clinical Implications: Supports considering CPC mouthwash as an adjunct to topical triamcinolone for erosive OLP to enhance symptom control and mucosal healing while favorably modulating Th17/Treg balance.
Key Findings
- Total effective rate was higher with CPC plus triamcinolone vs triamcinolone alone (95% vs 80%; P=0.022).
- Greater improvements in VAS pain (P=0.024), mucosal repair (P=0.002), and reduction in erosive area (P=0.021).
- Lower detection rates of Staphylococcus and Candida albicans in saliva with combination therapy (P<0.05).
- Immune modulation: decreased chemerin, Th17 cells, Th17/Treg ratio, IL-17 and TNF-α (P<0.001) and increased Treg cells and IL-10 (P=0.003).
- Improved oral health-related quality of life (larger OHIP-14 reduction; P<0.001) without increased adverse events; non-significant trend to lower 3-month recurrence (P=0.521).
Methodological Strengths
- Controlled two-arm clinical comparison with predefined outcomes and biomarker assessments.
- Multi-dimensional endpoints including clinical scores, microbiota detection, cytokines, and Th17/Treg metrics.
Limitations
- Non-randomized, single-center design with short follow-up (3 months) limits causal inference and durability assessment.
- Microbiota assessment based on detection rates with limited taxonomic resolution; blinding not reported.
Future Directions: Conduct randomized, blinded multicenter trials with longer follow-up, integrate high-resolution microbiome sequencing, and elucidate mechanistic links (e.g., chemerin pathways) to relapse prevention.
BACKGROUND: Oral lichen planus (OLP) is a chronic inflammatory disease associated with oral microbiome imbalance and immune dysregulation. OBJECTIVES: To evaluate the effects of CPC mouthwash combined with triamcinolone acetonide on oral microbiota and Th17/Treg balance in erosive OLP patients. METHODS: This study involved 80 patients with erosive OLP from January 2023 to January 2025. They were divided into: A control group treated with triamcinolone acetonide and a combination group treated with triamcinolone acetonide plus cetylpyridinium chloride mouthwash. After 4 weeks, primary outcomes included clinical efficacy, visual analog scale (VAS) pain scores, changes in signs and erosive area, oral salivary bacteria detection rate, Th17/Treg ratio, serum adipokine chemerin and cytokine levels (IL-17, TNF-α, IL-10) and OHIP-14 scores. Secondary outcomes were adverse reaction incidence and recurrence rates during follow-up. RESULTS: The combination group showed better outcomes after 4 weeks of treatment. The total effective rate was 95%, higher than the control group's 80% (P=0.022). The combination group had superior pain relief (P=0.024), better mucosal repair (P=0.002) and a significant decrease in erosive area (P=0.021). It also had lower oral detection rates of Staphylococcus and Candida albicans (P<0.05). Immunologically, the combination therapy significantly reduced serum levels of chemerin, Th17 cells, Th17/Treg ratio, IL-17 and TNF-α (P<0.001), while increasing Treg cells and IL-10 levels (P=0.003), indicating stronger anti-inflammatory and immune-balancing effects. The combination group showed a greater reduction in the OHIP-14 score (P < 0.001), indicating improved oral health-related quality of life. No significant difference in adverse reactions was observed (P>0.05) and all were mild. The combination group had a lower recurrence rate within 3 months post-treatment, although the difference was not statistically significant (P=0.521). CONCLUSION: The combination of cetylpyridinium chloride mouthwash with triamcinolone acetonide effectively regulates the oral microbiota structure and restores the Th17/Treg immune balance in OLP patients.
2. Spectrophotometric evaluation of sun protection and antioxidant potential of Artemisia maritima L. and Sophora mollis Royle from Hunza, Gilgit-Baltistan.
Spectrophotometric assays showed Artemisia maritima had a higher SPF (17.27) and stronger antioxidant capacity (higher TPC/TFC, lower IC50) than Sophora mollis, supporting its candidacy as a natural sunscreen component. Both species exhibited meaningful radical scavenging in ABTS and DPPH systems.
Impact: Identifies a high-altitude botanical with favorable SPF and antioxidant profile, informing development of natural photoprotective formulations in cosmetic dermatology.
Clinical Implications: Provides preclinical evidence to prioritize A. maritima in formulation screening for sunscreens and antioxidant-rich dermocosmetics, pending safety, stability, and in vivo efficacy testing.
Key Findings
- Artemisia maritima showed SPF 17.27 ± 0.31 versus 7.68 ± 0.18 for Sophora mollis.
- Higher total phenolic (345.93 ± 0.62 mg GAE/g) and flavonoid content (239.30 ± 0.47 mg QE/g) in A. maritima compared to S. mollis (297.38 ± 0.34 and 55.26 ± 0.75 mg/g).
- Antioxidant potency ranked Trolox (IC50 50.45 µg/mL) > A. maritima (119.52 µg/mL) > S. mollis (244.46 µg/mL).
- ABTS radical inhibition: 68.3% for A. maritima and 60.2% for S. mollis.
Methodological Strengths
- Multiple complementary assays (DPPH, ABTS, TPC, TFC) providing convergent evidence.
- Direct SPF estimation by spectrophotometry enabling rapid comparative screening.
Limitations
- In vitro spectrophotometric estimates may not translate to in vivo SPF or broad-spectrum (UVA/UVB) protection.
- No safety, photostability, formulation compatibility, or human skin testing reported.
Future Directions: Pursue bioassay-guided fractionation to identify active constituents, assess photostability and safety, and test efficacy in skin models and clinical trials.
BACKGROUND: Excessive ultraviolet (UV) radiation in mountainous regions increases the risk of skin disorders, highlighting the need for effective natural photoprotective agents. OBJECTIVES: This study aims to evaluate the sun protection factor (SPF) and antioxidant potential of two underexplored plants, Artemisia maritima and Sophora mollis, collected from high-altitude areas of Gilgit-Baltistan, to assess their suitability as natural photoprotective agents. METHODS: UV-Vis spectroscopy was used to assess free radical scavenging activity (DPPH and ABTS assays), along with total phenolic content (TPC) and total flavonoid content (TFC). RESULTS: A. maritima exhibited a higher SPF value (17.27 ± 0.31) compared to S. mollis (7.68 ± 0.18). Similarly, A. maritima showed greater TPC (345.93 ± 0.62 mg GAE/g) and TFC (239.30 ± 0.47 mg QE/g) than S. mollis (297.38 ± 0.34 mg GAE/g and 55.26 ± 0.75 mg QE/g, respectively). Antioxidant activity, measured by IC50 values, was strongest for Trolox (50.45 ± 0.97 µg/mL), followed by A. maritima (119.52 ± 2.23 µg/mL) and S. mollis (244.46 ± 8.06 µg/mL). In ABTS assays, A. maritima and S. mollis inhibited 68.3% and 60.2% of free radicals, respectively. CONCLUSION: These findings suggest that A. maritima possesses strong photoprotective and antioxidant properties, highlighting its potential as a promising natural sunscreen candidate, while S. mollis may provide moderate photoprotection suitable for complementary cosmetic or dermatological formulations.
3. Demonstrating Clinical Performance of the Elecsys Anti-SARS-CoV-2 Anti-Nucleocapsid Immunoassay Using Real-World Data to Support Regulatory Decision-Making in the USA.
A retrospective real-world analysis of 567 patients showed the Elecsys anti-nucleocapsid immunoassay achieved 96.49% positive percent agreement at ≥15 days post-symptom onset in non-immunocompromised individuals, meeting a prespecified ≥90% threshold. Performance was consistent across demographic subgroups, supporting regulatory use of RWD for diagnostic evaluation.
Impact: Validates a widely used SARS-CoV-2 serology assay using routine-care data with prespecified performance criteria, illustrating a pragmatic pathway for regulatory-grade evidence generation.
Clinical Implications: Supports deployment of anti-N serology for prior-infection ascertainment and surveillance, and demonstrates that well-curated real-world datasets can inform regulatory decisions on diagnostic tests.
Key Findings
- Among non-immunocompromised individuals at ≥15 DPSO (N=285), PPA was 96.49% (95% CI 93.66–98.08), exceeding the ≥90% threshold.
- Consistency of PPA across demographic subgroups supports generalizability.
- Dataset included 585 tests from 567 patients across DPSO categories (0–7: 77; 8–14: 45; ≥15 days: 463).
Methodological Strengths
- Prespecified primary endpoint (PPA ≥90%) and DPSO stratification to address seroconversion dynamics.
- Real-world dataset with de-duplication (first serology per DPSO category) to avoid repeated measures bias.
Limitations
- Retrospective single-center design limits control of confounding and external validity.
- Specificity and performance in immunocompromised or vaccinated individuals were not the primary focus.
Future Directions: Expand to multicenter RWD with standardized data models, assess specificity and seroreversion over time, and evaluate performance in immunocompromised and vaccinated populations.
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a global public health concern. Anti-nucleocapsid (anti-N) serology is a key tool for identifying prior infection and supporting population-level surveillance. This study evaluated the clinical performance of the Elecsys METHODS: We conducted a retrospective review of electronic medical records and laboratory information system data from patients who presented to Columbia University Irving Medical Center from March 2020 to March 2021. Eligible participants were symptomatic, unvaccinated individuals with PCR-confirmed SARS-CoV-2 infection who subsequently underwent serologic testing. Serologic results were categorized by days post symptom onset (DPSO): 0-7, 8-14, and ≥ 15 days. To avoid repeated measures, only the first serologic result per patient within each DPSO category was included. The primary endpoint was positive percent agreement (PPA) for nonimmunocompromised individuals tested at ≥ 15 DPSO, with a prespecified acceptance threshold of ≥ 90%. RESULTS: A total of 585 serologic tests from 567 patients (77, 45, and 463 samples, in DPSO categories of 0-7, 8-14, and ≥ 15 days, respectively) were evaluated. Among nonimmunocompromised individuals with samples collected ≥ 15 DPSO (N = 285), the PPA was 96.49% (95% confidence interval 93.66%, 98.08%), fulfilling the predefined acceptance criterion. PPA was also consistent across demographic subgroups, supporting the generalizability of the findings. CONCLUSIONS: This study demonstrates the feasibility of generating robust clinical evidence for regulatory purposes using real-world data. The clinical performance of the Elecsys Anti-SARS-CoV-2 immunoassay was confirmed using data collected under routine conditions during the pandemic, complementing data from controlled clinical studies and contributing to informed regulatory decision-making.